Clinical trial
Rituximab in Membranous Nephropathy
NCT00425217 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00425217 |
|---|---|
| Title | Rituximab in Membranous Nephropathy |
| Official title | The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Membranous Nephropathy |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 15 |
| Start date | Aug 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Jan 22, 2007 |
| Last update posted | Feb 25, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: